ArticleParasitology research2026
Antigenic profiling of Leishmania amazonensis microsomal fraction to support vaccine development.
Article in Parasitology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Vaccination remains the most promising long-term strategy for controlling leishmaniasis, as individuals who recover from primary infection generally develop protective immunity. However, no vaccine is currently available for human use. In this study, we identified two immunogenic proteins that may account for the protective effect previously observed with the Leishmania amazonensis microsomal fraction (MicF), which confers protection in murine models. Both proteins were expressed in Escherichia coli and used to immunize mice, eliciting specific humoral responses and promoting elevated production of Th1-associated cytokines. Considering the well-documented difficulty in inducing effective immunity against L. amazonensis, a species associated with diffuse cutaneous leishmaniasis and marked host anergy, the identification of these proteins as strong immunogens is noteworthy. Collectively, our findings provide preliminary evidence supporting the Leishmania homolog of receptors for activated C kinase (LACK) and phosphoenolpyruvate carboxykinase (PEPCK) as potential vaccine candidates against L. amazonensis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.